Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPOR | P19235 | 9/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809576 | 0.87 | EPOR (0.55) | EPORALOX5PTGS1PTGS2ALOX5AP | |
| SCHEMBL2914250 | 0.75 | GAA (0.50) | EPOR | |
| SCHEMBL2914248 | 0.75 | GAA (0.50) | EPOR | |
| SCHEMBL6808678 | 0.73 | EPOR (0.69) | EPORALOX5PTGS1PTGS2ALOX5AP | |
| SCHEMBL25951367 | 0.71 | ALOX5 (0.60) | EPORALOX5PTGS1PTGS2ALOX5AP | |
| SCHEMBL7086903 | 0.70 | ALOX5 (0.66) | EPORALOX5PTGS1PTGS2ALOX5AP | |
| SCHEMBL7086909 | 0.70 | ALOX5 (0.66) | EPORALOX5PTGS1PTGS2ALOX5AP | |
| SCHEMBL28871484 | 0.70 | ATM (0.52) | MAPTATM | |
| SCHEMBL3213833 | 0.70 | BACE1 (0.72) | EPORALOX5PTGS1PTGS2ALOX5AP | |
| SCHEMBL3213822 | 0.70 | BACE1 (0.72) | EPORALOX5PTGS1PTGS2ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1073623-B1 | SUBSTITUTED AMINO ACIDS AS ERYTHROPOIETIN MIMETICS | ORTHO MCNEIL PHARM INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-7153869-B2 | Substituted amino acids as erythropoietin mimetics | CONNOLLY PETER J | 2006-12-26 | — | — | US | disclosed |
| EP-1073623-A4 | SUBSTITUTED AMINO ACIDS AS ERYTHROPOIETIN MIMETICS | ORTHO MCNEIL PHARM INC (US) | 2004-08-18 | — | — | EP | disclosed |
| US-6750369-B2 | USEFUL IN TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH ERYTHROPOIETIN RECEPTOR | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020016350-A1 | Substituted amino acids as erythropoietin mimetics | CONNOLLY PETER J (US) | 2002-02-07 | — | — | US | disclosed |
| EP-1073623-A1 | SUBSTITUTED AMINO ACIDS AS ERYTHROPOIETIN MIMETICS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054279-A1 | SUBSTITUTED AMINO ACIDS AS ERYTHROPOIETIN MIMETICS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016350-A1 | Substituted amino acids as erythropoietin mimetics | EPOR, EDNRA, FLT1 | EPOR 1/4885ALOX5 3840/4885PTGS1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.